


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:


1. (Previously Presented) A purified compound of general formula **I**:



wherein R<sub>1</sub> are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl; R<sub>3</sub> groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl

R<sub>4</sub> groups are each independently selected from NR<sub>2</sub>, O and S; and R<sub>2</sub> groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

2. (Original) The compound according to claim 1, having the following formula **II**:




wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are as defined in claim 1.

3. (Previously Presented) The compound according to claim 1, wherein R<sub>1</sub> are each independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted alkylidene.


4. (Previously Presented) The compound according to claim 1, wherein R<sub>2</sub> are each independently selected from H and substituted or unsubstituted alkyl.

5. (Previously Presented) The compound according to claim 1, wherein  $R_3$  are each independently selected from H and substituted or unsubstituted aryl.
6. (Previously Presented) The compound according to claim 1, wherein  $R_4$  are each O.
7. (Previously Presented) The compound according to claim 1, having the following formula



or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

8. (Original) The compound according to claim 7, having the following stereochemistry



9. (Original) A process for producing a compound as defined in claim 1 which comprises synthesising a oxazole/thiazole/imidazole fragment, and introducing an aminoacidic fragment.

10. (Previously Presented) A process for preparing a compound as defined in claim 7 which comprises (i) cultivating a substantially pure culture strain ES7-008, available under accession number CECT 3358, from the Colección Española de Cultivos Tipo at the University of Valencia, Spain (ii) isolating said compound from the cultured broth.

Claims 11-13 (Cancelled)

14. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 1, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, and a pharmaceutically acceptable diluent or carrier.


15. (Cancelled)

16. (Cancelled)

17. (Previously Presented) A method of treatment of cancer which comprises administering an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

18. (Previously Presented) The process of claim 10, wherein the cultivating is performed in an aqueous nutrient medium with assimilable carbon and nitrogen sources and salts.


19. (New) The pharmaceutical composition according to claim 14, wherein the compound is a compound having the following formula **II**:



wherein  $R_1$  are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl;  $R_3$  groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl;  $R_4$  groups are each independently selected from  $NR_2$ , O and S; and  $R_2$  groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or


unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof..

20. (New) The pharmaceutical composition according to claim 14, wherein the compound is a compound having the following formula:



or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

21. (New) The pharmaceutical composition according to claim 14, wherein the compound is a compound having the following formula:



or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

22. (New) The method according to claim 17, wherein the compound is a compound having the following formula **II**:





wherein R<sub>1</sub> are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl; R<sub>3</sub> groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl; R<sub>4</sub> groups are each independently selected from NR<sub>2</sub>, O and S; and R<sub>2</sub> groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof..

CC(C)C(C)C(=O)NC(C)C(=O)NC(C)C(=O)Nc1cc2ccccc2o1Cn1cc2ccccc2o1Cn1cc2ccccc2o1Cn1cc2ccccc2o1Cn1cc2ccccc2o1Cn1cc2ccccc2o1Cn1cc2ccccc2o1

or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

[illegible]

or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.